CN105566300A - Novel alkaloid compound and preparation method and medical application thereof - Google Patents
Novel alkaloid compound and preparation method and medical application thereof Download PDFInfo
- Publication number
- CN105566300A CN105566300A CN201610040848.6A CN201610040848A CN105566300A CN 105566300 A CN105566300 A CN 105566300A CN 201610040848 A CN201610040848 A CN 201610040848A CN 105566300 A CN105566300 A CN 105566300A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- cell
- extract
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a novel alkaloid compound and a preparation method and medical application thereof. The compound is reported for the first time, is an alkaloid compound of a novel structure, and can be extracted from dry roots of radix lithospermi and obtained after separation and purification. It is proved through an in vitro test that the compound can remarkably restrain growth of melanoma cells and the number of the cells and the concentration of the compound (I) are in a dependent decrease relationship. The compound (I) is probably an effective targeted therapy drug for melanomas and can be developed into a drug for treating the melanomas.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to from the dry root of Asian puccoon, be separated obtain a kind of and there is alkaloid compound for the treatment of melanoma effect and preparation method thereof.
Background technology
Asian puccoon is the dry root of comfrey Arnebia euchroma Arnebiaeuchroma (Royle) Johnst., Asian puccoon LithospermumerythrorhizonSiebetZucc. or arnebia guttata Bunge ArnebiaguttataBunge.Asian puccoon begins to be loaded in Shennong's Herbal, and the successive dynasties, all book on Chinese herbal medicine was all documented.It is cold in nature, and taste is sweet, salty, the thoughts of returning home, Liver Channel, has the effect of the cool blood that stops blooding, be used for the treatment of that blood-head poison is contained, macula purple black, measles without adequate eruption, pyreticosis macula, eczema, hematuria, blood pouring, bloody flux, constipation with heat retention, sore, erysipelas, burn, evil sore, tinea etc.
Asian puccoon is utilized by extensively effective clinically, excites the research of people to Asian puccoon chemical composition.The research that the discovery of Asian puccoon chemical composition and machine-processed aspect deepen continuously, overcomes the difficult and complicated illness such as cancer, virus infection, acquired immune deficiency syndrome (AIDS) and provides foundation and class of medications for people.Containing number of chemical composition in Asian puccoon, comprise the materials such as naphthoquinones class, benzoquinones class, alkaloids, phenol, phenolic acids, triterpenic acid, sterols, flavonoid and polyose, what research was more at present is fat-soluble very strong naphthoquinone compound and water-soluble polysaccharide.Wherein naphthoquinones class is the anticancer main chemical compositions of Asian puccoon, and two kinds of molecular weight are respectively 27336, and the polysaccharide mixture of 1152 is main components of its anti-human papilloma virus (anti-HPV).
Asian puccoon all has restraining effect to various bacteria, fungi, virus (simplexvirus, human immunodeficiency virus).The natural naphthoquinones class chemical composition extracted from Asian puccoon has certain antitumor action.The synthesis of Asian puccoon to leukotriene and serotonin has restraining effect, the inflammatory mediator effects such as tool antihistamine, therefore utilizes this pharmacological action of Asian puccoon for preventing and treating the disease such as bronchial asthma, urticaria.Asian puccoon also can strengthen phagocytic function and the natural killer cell activity of scavenger cell, increases lymphocytic quantity, all has enhancement to mouse specificity and non-specific immunity.In addition; Asian puccoon also has the effects such as antifertility, hypoglycemic, anti-oxidant, immunomodulatory, promotion wound healing, ecchymose removing, promotion cutin abnormal restoring; clinically for contraception, treatment diabetes, liver lipids oxidative damage, wound, burn, scald, psoriatic etc.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry root of Asian puccoon, be separated obtain a kind of there is alkaloid compound for the treatment of melanoma effect and preparation method thereof.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula,
The preparation method of described compound (I), comprise following operation steps: the dry root of (a) Asian puccoon is pulverized, extract with 70 ~ 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, then use 70% ethanol elution, 12 column volumes, collect 70% ethanol eluate, concentrating under reduced pressure obtains 70% ethanol elution thing medicinal extract; C in () step (b), 70% ethanol elution thing medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,50:1,30:1,10:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 15:1,10:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, in step (a), extract with 75% alcohol heat reflux, united extraction liquid.
Further, described macroporous resin is AB-8 type macroporous adsorbent resin.
A kind of pharmaceutical composition, this pharmaceutical composition contains the compound according to claim 1 (I) for the treatment of significant quantity and pharmaceutically acceptable carrier.
The application of described compound (I) in the melanomatous medicine of preparation treatment.
The application of described pharmaceutical composition in the melanomatous medicine of preparation treatment.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that the theoretical ECD value of compound (I) compares with experiment ECD value;
Fig. 3 is BrdU Immunofluorescence test Cell proliferation results.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: compound (I) is separated preparation and structural identification
Reagent source: ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Asian puccoon is through being accredited as the dry root of arnebia guttata Bunge ArnebiaguttataBunge.
Preparation method: the dry root (8kg) of Asian puccoon is pulverized by (a), (25L × 3 time) are extracted with 75% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (3L), use sherwood oil (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated propyl carbinol (3L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (347g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract AB-8 type macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, use 70% ethanol elution, 12 column volumes again, collect 70% ethanol eluate, concentrating under reduced pressure obtains 70% ethanol elution thing medicinal extract (129g); C in () step (b), 70% ethanol elution medicinal extract purification on normal-phase silica gel is separated, successively with volume ratio be 80:1 (8 column volumes), the methylene chloride-methanol gradient elution of 50:1 (8 column volumes), 30:1 (6 column volumes), 10:1 (8 column volumes) and 1:1 (5 column volumes) obtains 5 components; D component 4 (31g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 15:1 (8 column volumes), the methylene chloride-methanol gradient elution of 10:1 (10 column volumes) and 5:1 (6 column volumes) obtains 3 components; E in () step (d), component 2 (14g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8-10 column volume elutriant, elutriant concentrating under reduced pressure obtains pure compound (I) (28mg).
Structural identification: light yellow oil; HR-ESIMS shows [M+Na]
+for m/z456.2312, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
26h
31n
3o
3, degree of unsaturation is 13.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 600MHz): H-3 (1.94, m), H-3 (2.31, m), H-7 (6.41, br, s), H-9 (7.45, d, J=8), H-10 (7.01, m), H-11 (7.09, m), H-12 (7.28, d, J=8), H-14 (1.62, m), H-14 (1.79, m), H-15 (3.41, br, d, J=7), H-17 (4.17, d, J=12), H-17 (4.38, d, J=12), H-18 (0.87, s), H-19 (2.02, m, 2H), H-21 (5.57, s), H-2 ' (8.28, br, s), H-4 ' (7.39, br, t, J=7), H-5 ' (7.05, m), H-6 ' (8.32, m), H-7 ' (3.19, m), H-8 ' (1.18, br, d, J=8), 16-CO
2me (3.71, s), NH (9.82, br, s), carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 150MHz): 135.4 (C, 2-C), 45.7 (CH
2, 3-C), 101.3 (CH, 7-C), 127.2 (C, 8-C), 119.8 (CH, 9-C), 119.3 (CH, 10-C), 121.4 (CH, 11-C), 110.6 (CH, 12-C), 135.7 (C, 13-C), 25.8 (CH
2, 14-C), 38.7 (CH, 15-C), 57.3 (C, 16-C), 65.5 (CH
2, 17-C), 12.7 (CH
3, 18-C), 25.7 (CH
2, 19-C), 115.1 (C, 20-C), 131.9 (CH, 21-C), 148.8 (CH, 2 '-C), 132.7 (C, 3 '-C), 134.5 (CH, 4 '-C), 123.8 (CH, 5 '-C), 148.1 (CH, 6 '-C), 61.0 (CH, 7 '-C), 18.9 (CH
3, 8 '-C), 173.8 (C, 16-CO
2me), 52.2 (CH
3, 16-CO
2me), carbon atom mark is see Fig. 1.IR spectrum shows that this compound contains amido, hydroxyl (3380cm
-1) and ester carbonyl group (1725cm
-1); UV spectrum demonstrates characteristic absorption band 231,282 and the 290nm of indoles.
1hNMR composes display eight aromatics resonance signals (δ H7.01,7.05,7.09,7.28,7.39,7.45,8.28,8.32), an indoles NH (δ H9.82), a methyl ester group (δ H3.71), methylol (δ H4.17,4.38; D, J=12Hz), a CHMe (δ H1.18,3.19) and an ethyl side chains (δ H0.87,2.02).
13cNMR composes 26 carbon and shows 26 resonance carbon signals, comprises three methyl, four methylene radical, 12 methynes, four quaternary carbons, an ester carbonyl group, and has two tertiary carbons (C-2 with C-13) to be connected with indole nitrogen.Known according to COSY spectrum, there are continuous four to be assigned to (H-9, H-10, H-11 and H-12) in indole structure in eight fragrant hydrogen of resonance.The NOE dependency of fragrance Hydrogen Proton bimodal signal δ H7.28 and indoles NH (δ H9.88) shows that this bimodal signal is H-12, and another bimodal signal δ H7.45 is H-9.In addition, the NOE dependency of H-9 and the unimodal δ H6.41 of another aromatic series Hydrogen Proton (δ C101.3) shows that these hydrogen is similar to, and this shields the H-7 that aromatic is 6,7-open loop monoterpene indoles relatively.Other four fragrant hydrogen of resonance, the existence of five aromatic series carbon signals (δ C123.8,132.7,134.5,148.1 and 148.8) and mass-spectrometric data tertiary amine, shows that this compound contains a 3-substituted pyridines ring.The distinctive proton of pyridine moiety and carbon signal δ H8.28 (δ C148.8) and δ H8.32 (δ C148.1) demonstrate above-mentioned inference.From
1the alkyl substituent that HNMR composes known pyridine moiety C-3 ' position is-CHCH
3, this group is connected with the N-4 position of monoterpene indoles.Quaternary carbon C-16 (δ C57.3) is connected with a methylol and methoxycarbonyl, is connected with the C-2 of indolyl moiety, while 2, the 3-dehydropiperidine parts being contained the ethyl pyridinyl replacement of ethyl side chains by C-15 and C-20 position are connected.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and NOESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
People A375 melanoma cell strain is given by Third Military Medical University.Compound (I) is made by oneself, and preparation method is shown in that embodiment 1, HPLC normalization method purity is greater than 98%.DMEM substratum, 0.25% pancreatin purchased from American Gibco company.MTT (3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide bromine salt; Methyl thiazoly tetrazolium assay), DMSO (dimethyl sulfoxide (DMSO)), BrdU purchased from American Sigma company.Mouse-anti BrdU polyclonal antibody purchased from American ABcam company.Goat against murine two anti-purchased from American Cellsignaling company.AnnexinV-FITC/PI cell apoptosis detection kit purchased from American Promega company.
Constant temperature CO
2incubator, general refrigerator ,-80 degree refrigerators are U.S. Forma Products.Bechtop (Chinese Suzhou cleaning project company).Inverted microscope, inverted fluorescence microscope (olympus company).Electro-heating standing-temperature cultivator (Chinese Shanghai leap medical apparatus and instruments factory).Automatic microplate reader (Japanese Wako company).UV detector (Beckman company of the U.S.).J6-HC supercentrifuge (Beckman company of the U.S.).Low-temperature trace whizzer (German Eppendorf company).Vibration shaking table (Forma company of the U.S.).
Two, test method
1, cell cultures
1.1 cell recovery
Frozen A375 melanoma cell in liquid nitrogen container taken out, put into rapidly the warm water of 37 DEG C, shake makes it melt as early as possible (about lmin) gently.Then sucking-off cell suspension, joins in the centrifuge tube being added with 2mL substratum, blows and beats mixing gently, 800r/min, and centrifugal 5min discards upper strata substratum.After making cell suspension with the DMEM substratum 8mL of the mould G/ Streptomycin sulphate containing 10%FBS and 1%, be seeded in 10cm culture plate.Then 5%CO is placed in
2, cultivate in 37 DEG C of constant incubators.
1.2 passage
Basis of microscopic observation cytogamy degree can go down to posterity when reaching 80%-90%.First use 2mLPBS washed cell 2 times, then add the pancreatin lmL of 0.25%.Horizontal wave and culture dish gently, makes Digestive system can cover the surface of cell, is then placed in 37 DEG C of incubators and digests about lmin.See that cell rounding bounces back under being placed in microscope, then add rapidly the substratum termination digestion that 1mL contains FBS.Blow and beat to cell dispersal even gently, then go down to posterity according to 1:2 or 1:3 according to cell density, be re-seeded in new culture plate, be placed in 5%CO
2, cultivate in 37 DEG C of constant incubators.
1.3 cell cryopreservation
Get the cell that 1 dish is in logarithmic phase, trysinization is also collected in centrifuge tube, and the centrifugal 5min of 1000r/min, abandons supernatant.Then add lmL frozen storing liquid, dispel cell gently and make cell suspension, cell suspension is joined in the cryopreservation tube of 1.5mL.In the title of cryopreservation tube subscript clear-cells, shelf time, the name of preserver.First cryopreservation tube is put into 4 DEG C of refrigerators, place about 30min.Then be placed in-20 DEG C of refrigerators, place about 2h.Then be put in-80 DEG C of Ultralow Temperature Freezers to place and spend the night.Frozen cell was placed in the medium-term and long-term preservation of liquid nitrogen container in second day.
2, cell counting draws cell growth curve
(1) take the logarithm A375 melanoma cell in vegetative period, counting, adjustment cell density is 2 × 10
4/ mL.
(2) by cell suspension inoculation in 12 orifice plates, 1.5mL/ hole.
(3) after 12h, treat cell attachment, change 1mL plasma-free DMEM medium, and use 5 μm of ol/L compounds (I) and DMSO (for the compound (I) of DMSO dilution respectively, control DMSO concentration is below 1/1000, guarantee cell harmless) process, often organize cell and establish 3 parallel holes, be placed in 5%C02,37 DEG C of constant incubators are cultivated.
(4) stop cultivating respectively at 0h, 24h, 48h, 72h, 96h, collect each group of cell, add 0.25% tryptic digestion, centrifugal, resuspended.
(5) cell counting: draw cell suspension 10 μ L, add isopyknic phenol blue area and divide viable cell, draw 10 μ L mixed solutions and add in cell counting count board groove gently, ensure tight and bubble.Under inverted microscope, the cell count in counting periphery four block plaid, substitutes into formula: archeocyte suspension concentration (cell count/mL)=(cell count/4 of 4 block plaid) × 10
4× extension rate.
(6) calculate number of viable cells, draw cell growth curve.
3, mtt assay detects cell proliferation
(1) the A375 cell of taking the logarithm vegetative period, digestion, centrifugal, resuspended, counting, in adjustment cell suspension, the density of cell is 2 × 10
4/ mL.
(2) by each group of cell suspension inoculation in 96 well culture plates, the 200 every holes of μ L, often organize cell 3 parallel holes, establish blank control wells (only adding substratum) simultaneously.
(3) 12h is after cell attachment, changes 200 μ L plasma-free DMEM medium, and uses 5 μm of ol/L compounds (I) and DMSO process respectively.
(4) stopped cultivating respectively at 0,1,2,3,4 day.
(5) add Methyl thiazoly tetrazolium assay (MTT) the 20 μ L that concentration is 5mg/mL to every hole and continue culturing cell 4h.
(6) inhale the substratum abandoned in each aperture, add 200 μ LDMSO, microoscillator is vibrated 10min, and crystallisate is fully dissolved.
(7) return to zero with blank control wells, automatic microplate reader is adopted to measure the absorption photometric value (OD value) at 570nm place, each hole, ability of cell proliferation is represented with the OD value of correspondence, the each group of mean value getting 3 parallel holes, take time as transverse axis, with each absorbance for the longitudinal axis draws cell growth curve.
4, BrdU Immunofluorescence test cell proliferation
(1) creep plate is prepared: creep plate is put into 75% alcohol and soak 24h and disinfect.
(2) aseptic creep plate is placed in 24 well culture plates, the A375 melanoma cell in vegetative period of taking the logarithm, digestion, centrifugal, make cell suspension, 2 × 10
4cell/ hole, is inoculated in and is placed with in the hole of creep plate.
(3) 12h is after cell attachment, changes 1mL plasma-free DMEM medium, and uses 5 μm of ol/L compounds (I) and DMSO process respectively.
(4) after 72h, add 10 μ lBrdU (1mg/mL) in the medium, cultivate 1h for 37 DEG C.
(5) take out 24 orifice plates, wash 5min × 2 time with cold PBS, 4% paraformaldehyde fixed cell, room temperature 30min.
(6) PBS washes 5min × 3 time.
(7) 2mol/LHCl process, after room temperature 10min, 37 DEG C of 20min.
(8) the penetrating process in cell 1%Triton ×-100, washes 5min × 3 time.
(9) 10% lowlenthal serums are closed, room temperature, lh.
(10) BrdU monoclonal antibody (1:300 dilution) is added, 37 DEG C of 1.5h.
(11) l × PBST shakes and washes 5min × 3 time.
(12) add BrdU bis-anti-(1:300), after room temperature lucifuge 1h, l × PBST washes 3 times.
(13) DAPI staining fluid transfect cell core 15min.
(14) PBS washes 5min × 3 time.
(15) 1 anti-fluorescent quenching mounting liquid is added, neutral gum mounting, fluorescence microscopy Microscopic observation, photograph.
5, statistical study
Application SPSS17.0 statistical analysis software, adopt two independent samples t test and one-way analysis of variance to carry out data analysis, data X ± S represents, P<0.05 is for there being statistical significance.
Three, result and conclusion
Cellular form is observed and counting display, and with DMSO control group ratio, after compound (I) process A375 cell 24h, 48h, 72h, viable count significantly reduces and reaches 44.5%.The results are shown in Table 1 (with control group ratio
*p<0.05,
*p<0.01, lower same).
MTT result shows, and compound (I) can significantly suppress A375 cell proliferation, and OD value is that the decline of concentration (5 μm of ol/L, 10 μm of ol/L, 20 μm of ol/L) dependency reaches 27.3%, and difference has statistical significance.The results are shown in Table 2.
Compound (I) energy check melanin tumor cell proliferation is confirmed further by BrdU immunofluorescence dyeing, 5 μm of ol/L compound (I) process A375 cells are after 3 days, compared with contrast (26.07 ± 2.59%), experimental group BrdU positive cell percentage (7.55 ± 2.76%) significantly reduces (P=0.000).The results are shown in Figure 3 (* * P<0.01).
This experiment have detected the impact that compound (I) is bred melanoma cell, cell counting and MTT analytical results all prove that compound (I) can remarkable check melanin tumor cell growth, and cell count and compound (I) concentration are that dependency declines.After BrdU immunofluorescence dyeing also shows compound (I) process, BrdU positive cell percentage is significantly lower than control group, illustrates that compound (I) can suppress A375 melanoma cell to be bred.Compound (I) may be melanomatous efficient targeting medicine.
Table 1 compound (I) dose-dependent inhibition A375 cell proliferation
(cell counting, unit: × l0
4/ mL)
| Group | 0h | 24h | 48h | 72h | 96h |
| DMSO | 2.87±0.23 | 4.72±0.30 | 7.36±0.13 | 7.56±0.39 | 8.04±0.27 |
| Compound (I)-5 μm of ol/L | 2.87±0.23 | 3.87±0.36* | 3.48±0.32** | 3.40±0.34** | 2.54±0.41** |
| Compound (I)-10 μm of ol/L | 2.87±0.23 | 2.36±0.28** | 2.95±0.37** | 1.56±0.36** | 0.89±0.26** |
Table 2 compound (I) dose-dependent inhibition A375 cell proliferation (mtt assay, OD570)
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:9 in itself and excipient weight.
Embodiment 4
Prepared by oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula,
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry root of Asian puccoon is pulverized by (a), extract with 70 ~ 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, then use 70% ethanol elution, 12 column volumes, collect 70% ethanol eluate, concentrating under reduced pressure obtains 70% ethanol elution thing medicinal extract; C in () step (b), 70% ethanol elution thing medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,50:1,30:1,10:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 15:1,10:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: in step (a), extracts, united extraction liquid with 75% alcohol heat reflux.
4. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is AB-8 type macroporous adsorbent resin.
5. a pharmaceutical composition, is characterized in that: this pharmaceutical composition contains the compound according to claim 1 (I) for the treatment of significant quantity and pharmaceutically acceptable carrier.
6. the application of compound according to claim 1 (I) in the melanomatous medicine of preparation treatment.
7. the application of pharmaceutical composition according to claim 5 in the melanomatous medicine of preparation treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610040848.6A CN105566300A (en) | 2016-01-21 | 2016-01-21 | Novel alkaloid compound and preparation method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610040848.6A CN105566300A (en) | 2016-01-21 | 2016-01-21 | Novel alkaloid compound and preparation method and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105566300A true CN105566300A (en) | 2016-05-11 |
Family
ID=55876992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610040848.6A Pending CN105566300A (en) | 2016-01-21 | 2016-01-21 | Novel alkaloid compound and preparation method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105566300A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105061548A (en) * | 2015-08-19 | 2015-11-18 | 庄立 | Novel withanolides compound and preparation method and medical application thereof |
| CN105566342A (en) * | 2015-12-22 | 2016-05-11 | 潘豪杰 | Novel diterpenoid for treating melanoma and preparation method thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102695417A (en) * | 2009-11-06 | 2012-09-26 | 普莱希科公司 | Compounds and methods for kinase modulation, and indications therefor |
| CN105061548A (en) * | 2015-08-19 | 2015-11-18 | 庄立 | Novel withanolides compound and preparation method and medical application thereof |
| CN105061456A (en) * | 2015-09-13 | 2015-11-18 | 周午贤 | Novel kaurene diterpenoid compound and preparation method and pharmaceutical application thereof |
| CN105294619A (en) * | 2015-10-21 | 2016-02-03 | 淄博夸克医药技术有限公司 | Novel diterpene compound and preparation method and medical application thereof |
| CN105330674A (en) * | 2015-12-07 | 2016-02-17 | 西宁意格知识产权咨询服务有限公司 | New diterpenoid compound and preparation method and medical application thereof |
| CN105481881A (en) * | 2015-12-30 | 2016-04-13 | 吴金凤 | Novel diterpene alkaloid compound and preparation method and medical application thereof |
| CN105503999A (en) * | 2015-12-31 | 2016-04-20 | 吴金凤 | Limonin compounds for treating melanoma and preparation method thereof |
| CN105524075A (en) * | 2015-12-29 | 2016-04-27 | 吴金凤 | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound |
| CN105566342A (en) * | 2015-12-22 | 2016-05-11 | 潘豪杰 | Novel diterpenoid for treating melanoma and preparation method thereof |
-
2016
- 2016-01-21 CN CN201610040848.6A patent/CN105566300A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102695417A (en) * | 2009-11-06 | 2012-09-26 | 普莱希科公司 | Compounds and methods for kinase modulation, and indications therefor |
| CN105061548A (en) * | 2015-08-19 | 2015-11-18 | 庄立 | Novel withanolides compound and preparation method and medical application thereof |
| CN105061456A (en) * | 2015-09-13 | 2015-11-18 | 周午贤 | Novel kaurene diterpenoid compound and preparation method and pharmaceutical application thereof |
| CN105294619A (en) * | 2015-10-21 | 2016-02-03 | 淄博夸克医药技术有限公司 | Novel diterpene compound and preparation method and medical application thereof |
| CN105330674A (en) * | 2015-12-07 | 2016-02-17 | 西宁意格知识产权咨询服务有限公司 | New diterpenoid compound and preparation method and medical application thereof |
| CN105566342A (en) * | 2015-12-22 | 2016-05-11 | 潘豪杰 | Novel diterpenoid for treating melanoma and preparation method thereof |
| CN105524075A (en) * | 2015-12-29 | 2016-04-27 | 吴金凤 | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound |
| CN105481881A (en) * | 2015-12-30 | 2016-04-13 | 吴金凤 | Novel diterpene alkaloid compound and preparation method and medical application thereof |
| CN105503999A (en) * | 2015-12-31 | 2016-04-20 | 吴金凤 | Limonin compounds for treating melanoma and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 张艳丽: "NTSR1拮抗剂SR48692对黑色素瘤细胞增殖、凋亡的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 郭鑫等: "新疆紫草化学成分的初步研究", 《时珍国医国药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105061548A (en) * | 2015-08-19 | 2015-11-18 | 庄立 | Novel withanolides compound and preparation method and medical application thereof |
| CN105566342A (en) * | 2015-12-22 | 2016-05-11 | 潘豪杰 | Novel diterpenoid for treating melanoma and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105061456A (en) | Novel kaurene diterpenoid compound and preparation method and pharmaceutical application thereof | |
| CN104961791B (en) | A kind of new triterpenoid, preparation method and purposes in Radix potentillae anserinae | |
| CN105481881A (en) | Novel diterpene alkaloid compound and preparation method and medical application thereof | |
| CN105330636A (en) | New flavonoid compound and preparation method and medical application thereof | |
| TWI648257B (en) | Compounds from antrodia camphorata, method for preparing the same and use thereof | |
| CN105061548A (en) | Novel withanolides compound and preparation method and medical application thereof | |
| CN105330674A (en) | New diterpenoid compound and preparation method and medical application thereof | |
| CN105175481A (en) | Highly-oxidized diterpenoid compound and preparation method and medical application thereof | |
| CN105330673A (en) | Novel limonin compound and preparation method and medical application thereof | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN105503999A (en) | Limonin compounds for treating melanoma and preparation method thereof | |
| CN105330714A (en) | Novel limonin compound as well as preparation method and medical application thereof in treatment of prostatic cancer | |
| CN105524075A (en) | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound | |
| CN105218617A (en) | A kind of new triterpenoid and preparation method thereof and medicinal use | |
| CN105418562A (en) | Diterpenoid compound used for treating the prostatic cancer and preparation method therefor | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105566300A (en) | Novel alkaloid compound and preparation method and medical application thereof | |
| CN105566427A (en) | Lanostane triterpene compound, and preparation method and medicinal use thereof | |
| CN105566342A (en) | Novel diterpenoid for treating melanoma and preparation method thereof | |
| CN105294619A (en) | Novel diterpene compound and preparation method and medical application thereof | |
| CN105503778A (en) | Grayanotoxin compound and preparation method and medical application thereof | |
| CN105153263A (en) | New limonin compound as well as preparation method and medical application thereof | |
| CN105524063A (en) | Novel terpene indole alkaloid compound, and preparation method and medical application thereof | |
| CN105503991A (en) | Limonin compound for treating breast cancer and preparation method of limonin compound | |
| CN105503871A (en) | Novel indole alkaloid compound and preparation method and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160511 |
|
| WD01 | Invention patent application deemed withdrawn after publication |